Advertisements
Feeds:
Posts
Comments

Search Results for 'Statins'

Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease, Vascular Diseases, tagged , , , , on December 29, 2016| Leave a Comment »


Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 2/25/2019 https://www.medpagetoday.com/cardiology/prevention/78202?xid=nl_mpt_SRCardiology_2019-02-25&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CardioUpdate_022519&utm_term=NL_Spec_Cardiology_Update_Active While nearly 10% of middle-age adults in China have high risk for cardiovascular disease, only 0.6% of these high-risk individuals use statins and 2.4% […]

Read Full Post »

Perioperative Statins at Noncardiac Surgery: Survival Up, Complications Down

Posted in Perioperative Statins at Noncardiac Surgery on December 27, 2016| Leave a Comment »


Perioperative Statins at Noncardiac Surgery: Survival Up, Complications Down Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 11/26/2018   Clinical Trial: Statins Evaluation in Coronary Procedures and Revascularization (SECURE-PCI) A Cardio-Endo Connection selection by Dharam J. Kumbhani, MD, SM (Trial Summary); Deepak L. Bhatt, MD, MPH (Summary Reviewer) Contribution to Literature: The Statins Evaluation in Coronary […]

Read Full Post »

What’s the Story with Statins and Stroke Prevention? – A Q&A with Koto Ishida, MD – HCPLive

Posted in Uncategorized on January 30, 2015| Leave a Comment »


What’s the Story with Statins and Stroke Prevention? – A Q&A with Koto Ishida, MD HCPLive My patients are at high risk for future cardiovascular (CV) events; most have already had a stroke or a transient ischemic attack (TIA). Source: news.google.com See on Scoop.it – Cardiovascular and vascular imaging

Read Full Post »

Guideline Critics Shift Attacks From Beta Blockers To Statins – Forbes

Posted in Uncategorized on August 4, 2014| Leave a Comment »


Guideline Critics Shift Attacks From Beta Blockers To Statins Forbes With the release today of updated European and US guidelines the ongoing controversy regarding beta-blockers appears to be resolved. Source: http://www.forbes.com See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY

Read Full Post »

Statins in Very Elderly Adults (Debate) – Medscape

Posted in Scoop.it on July 1, 2014| Leave a Comment »


Medscape Statins in Very Elderly Adults (Debate) Medscape It contrasted the effects of intensive statin therapy with those of moderate statin therapy on reduction of myocardial ischemia in participants.

Read Full Post »

Statins cut limb events in PAD patients – Family Practice News Digital Network

Posted in Uncategorized on September 16, 2013| Leave a Comment »


See on Scoop.it – Cardiovascular and vascular imaging Statins cut limb events in PAD patients Family Practice News Digital Network “This is one of the first, and largest, studies to demonstrate an impact [of statin treatment] on adverse limb outcomes in patients with PAD, including worsening… See on http://www.familypracticenews.com

Read Full Post »

Statins’ Nonlipid Effects on Vascular Endothelium through eNOS Activation

Posted in Biological Networks, Gene Regulation and Evolution, Cardiovascular Pharmacogenomics, Cell Biology, Signaling & Cell Circuits, Disease Biology, Small Molecules in Development of Therapeutic Drugs, HTN, Metabolomics, Molecular Genetics & Pharmaceutical, Nitric Oxide in Health and Disease, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease, Proteomics, tagged , , , on October 8, 2012| 20 Comments »


Statins’ Nonlipid Effects on Vascular Endothelium through eNOS Activation   Curator, Author,Writer, Reporter: Larry Bernstein, MD, FACP   Categories of Research: Disease biology, Cell Biology and Cell Signaling, Biological Networks and Gene Regulation, Pharmacotherapy of Cardiovascular Disease, Nitric Oxide, HMG Co A inhibitors, Endothelial Receptor, Hypertension, Therapeutic Targets Introduction Statins have an effect on the […]

Read Full Post »

Hypertriglyceridemia: Evaluation and Treatment Guideline

Posted in Biomarkers & Medical Diagnostics, Biomedical Measurement Science, Cardiovascular Pharmacogenomics, Cardiovascular Research, Chemical Biology and its relations to Metabolic Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH), Clinical Diagnostics, Clinical Genomics, Diabetes Mellitus, Disease Biology, Endocrine Diseases, Epigenetics and Cardiovascular Risks, Frontiers in Cardiology and Cardiovascular Disorders, Lipid metabolism, Liver & Digestive Diseases Research, Metabolism, Myocardial Metabolism, Nutrition, Nutrition Disorders, Nutritional Supplements: Atherogenesis, lipid metabolism, Obesity, Origins of Cardiovascular Disease, Pancreatic adenocarcinoma classifier, Pancreatic cancer, Population Health Management, Population Health Management, Genetics & Pharmaceutical, tagged , , , , , , on January 22, 2019| 1 Comment »


Hypertriglyceridemia: Evaluation and Treatment Guideline Reporter and Curator: Dr. Sudipta Saha, Ph.D.   Severe and very severe hypertriglyceridemia increase the risk for pancreatitis, whereas mild or moderate hypertriglyceridemia may be a risk factor for cardiovascular disease. Individuals found to have any elevation of fasting triglycerides should be evaluated for secondary causes of hyperlipidemia including endocrine […]

Read Full Post »

Advantages and Disadvantages of Novel Oral Anticoagulants (NOACs)

Posted in Coagulation Therapy and Internal Bleeding, tagged , , , , on March 20, 2018| Leave a Comment »


Advantages and Disadvantages of Novel Oral Anticoagulants (NOACs)   Reporter: Aviva Lev-Ari, PhD, RN     UPDATED ON 2/1/2019 NOACs Usually Preferable to Warfarin in Atrial Fibrillation: Guideline Update READ ALL GUIDELINES at the sources listed below. Here we post only, Triple vs Double Antithrombotic Therapy The update provides a warning about the extra bleeding […]

Read Full Post »

FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease on December 1, 2017| Leave a Comment »


FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease Reporter: Aviva Lev-Ari, PhD, RN   Evolocumab was first FDA approved in 2015 for patients with familial hypercholesterolemia and others who fail to achieve LDL cholesterol lowering through diet and […]

Read Full Post »

Next »